1-3 of 3
Nuria Navarro Coy
Close
Sort by
Journal Articles

Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation

Clinical Trials & Observations
Gareth J. Morgan, Faith E. Davies, Walter M. Gregory, Nigel H. Russell, Sue E. Bell, Alexander J. Szubert, Nuria Navarro Coy, Gordon Cook, Sylvia Feyler, Jenny L. Byrne, Huw Roddie, Claudius Rudin, Mark T. Drayson, Roger G. Owen, Fiona M. Ross, Graham H. Jackson, J. Anthony Child, for the NCRI Haematological Oncology Study Group
Journal: Blood
Blood (2011) 118 (5): 1231–1238.
https://doi.org/10.1182/blood-2011-02-338665
Published: 2011
Includes: Supplemental data
Journal Articles

Thalidomide Maintenance Significantly Improves Progression-Free Survival (PFS) and Overall Survival (OS) of Myeloma Patients When Effective Relapse Treatments Are Used: MRC Myeloma IX Results

Gareth J Morgan, MD, PhD, Faith E. Davies, MD, Walter M. Gregory, PhD, Sue E. Bell, PhD, Alex J. Szubert, MSc, Nuria Navarro-Coy, MPhil, Mark T. Drayson, MD, PhD, Roger G. Owen, MD, Gordon Cook, MD, Fiona M. Ross, PhD, Graham H. Jackson, MD, J. Anthony Child, MD
Journal: Blood
Blood (2010) 116 (21): 623.
https://doi.org/10.1182/blood.V116.21.623.623
Published: 2010
Journal Articles

The Addition of Thalidomide to the Induction Treatment of Newly Presenting Myeloma Patients Increases the CR Rate Which Is Likely to Translate Into Improved PFS and OS.

Gareth J Morgan, MD, PhD, Faith E Davies, MD, Walter M Gregory, Susan E Bell, Alex J Szubert, Kim Cocks, Nuria Navarro Coy, Mark T Drayson, Roger G Owen, Fiona M Ross, DPhil, Graham H Jackson, J. Anthony Child
Journal: Blood
Blood (2009) 114 (22): 352.
https://doi.org/10.1182/blood.V114.22.352.352
Published: 2009